Last updated: May 21, 2026
Executive summary
- Buphenyl is marketed in the US as sodium phenylbutyrate for chronic management of hyperammonemia in adult and pediatric patients with urea cycle disorders (UCDs). The most relevant clinical development focus remains genetic UCD populations and next-generation formulations/administration routes, not broad new indications.
- Market outlook is driven by: (1) UCD diagnosis incidence and referral patterns, (2) payer coverage constraints tied to specialty drug handling, (3) competition from glycerol phenylbutyrate (RAVICTI) and other ammonia-lowering agents, and (4) ongoing safety/efficacy evidence generation supporting long-term chronic use.
- For business planning, the “actionable” projection for Buphenyl is less about near-term label expansion and more about share protection and patient persistence while competing drugs and potential future reformulations compete on tolerability and dosing convenience.
What patents protect Buphenyl (sodium phenylbutyrate) and how strong is the patent estate?
Answer (featured snippet): The core Buphenyl active ingredient is sodium phenylbutyrate, and the US product sits in a landscape where compound-level protection is long expired; current exclusivity and protection typically come from formulation, process, and method-of-use patents plus regulatory exclusivities (where applicable) tied to specific approvals and labeling.
Patent estate coverage by layer (what matters for infringement and entry)
1) API (sodium phenylbutyrate) composition and early processes
- Typically long-expired for sodium phenylbutyrate, which has been in use for years.
- Risk for additional entry is generally higher if protection rests only on generic-comparable API equivalence.
2) Formulation and dosing-device IP
- For ammonia-lowering therapies, formulation IP targets:
- oral dosing constraints
- taste-masking and patient adherence
- stability and manufacturing yield
- pediatric dosing flexibility (granules/tablets or equivalent presentations)
- Litigation risk tends to concentrate around:
- manufacturing process steps
- specific excipient systems
- specific particle-size/solubility/stability targets
3) Method-of-use and regimen IP
- Method-of-use claims in this category typically address:
- chronic dosing regimens
- titration approaches
- monitoring-based adjustment strategies
- specific UCD subtypes
Practical strength assessment for commercial strategy
- If the US Orange Book lists only a narrow set of patents for Buphenyl (or listed patents are expired/near expiry), then the barrier to generic entry becomes primarily a function of:
- existing FDA labeling and listed exclusivities
- whether any active formulation/process patents remain in force
- whether any Paragraph IV challenges are pending against listed patents (which can force settlements that distort timing)
(Note: This topic requires Orange Book and specific listed patent numbers to quantify “how many patents” remain active and their expiration dates. Without those listings in the current prompt, no complete, accurate patent map can be produced.)
When does Buphenyl lose exclusivity in the US, and what is the generic entry risk?
Answer (featured snippet): Buphenyl’s active ingredient is not expected to be protected by a still-active compound patent in the US, so exclusivity timing hinges on any remaining listed patents (formulation/process/method-of-use) and any regulatory exclusivities tied to a specific Buphenyl NDA/labeling revision.
What determines FDA exclusivity and entry timing in practice
- Orange Book patent status
- Listed patents with in-force status define the immediate “entry risk window.”
- Formulation equivalence
- Even if the API is old, generics can face extra data generation if product characteristics differ materially.
- Settlements after Paragraph IV filings
- Where applicable, settlement terms can create deferred entry dates independent of statutory expiration.
(Note: Accurate exclusivity dates require the exact Orange Book record for the Buphenyl NDA and listed patents.)
What is the FDA regulatory status of Buphenyl for urea cycle disorders (UCDs)?
Answer (featured snippet): Buphenyl is approved for chronic management of hyperammonemia in UCDs. Its regulatory posture is that of a mature, specialty chronic therapy.
Key regulatory features that shape adoption
- Patient population: pediatric and adult UCD patients requiring lifelong ammonia control.
- Specialty drug requirements: cold-chain is not typically central to phenylbutyrate products, but dispensing and dose management are specialty-intensive.
- Clinical outcome metrics: ammonia control and reduction of hyperammonemic episodes, plus tolerability and adherence.
(Note: A complete regulatory timeline (approval date, supplements, exclusivity codes, labeling changes) requires direct FDA label/NDA/Orange Book inputs.)
How does Buphenyl compare with glycerol phenylbutyrate (RAVICTI) on efficacy, safety, and adherence?
Answer (featured snippet): Both target ammonia control in UCDs through phenylbutyrate delivery, but the main differentiators in commercial practice are dosing convenience and tolerability profile, which influence adherence and payer/physician selection.
High-level differentiation points used in market selection
- Dosing practicality
- Liquid phenylbutyrate delivery can improve day-to-day adherence versus larger pill burdens or granule preparation steps depending on local product form.
- Patient tolerability
- Gastrointestinal tolerability often drives switching in chronic therapy.
- Specialist prescribing behavior
- UCD centers often build protocol-driven formularies based on patient history.
Commercial implication
- Even with similar ammonia-lowering pharmacologic endpoints, convenience and tolerability can translate into shift in market share away from older or less convenient regimens.
(Note: Quantitative comparisons require trial-level endpoints and label data.)
What clinical trials have been completed, are ongoing, or newly updated for Buphenyl?
Answer (featured snippet): For sodium phenylbutyrate in UCDs, the clinical evidence base is largely mature, with current activity often shifting toward:
- longer-term safety in chronic use
- pediatric pharmacology and regimen optimization
- formulation-specific pharmacokinetic comparisons rather than new phase-3 efficacy programs
What “updates” usually look like for this class
- Protocol amendments to support chronic pediatric dosing
- Extension studies focusing on:
- ammonia levels
- nutritional status
- growth and development monitoring
- Smaller bioequivalence or PK bridging studies for reformulations
(Note: A concrete “clinical trials update” requires trial registry identifiers, status changes, and dates. The prompt does not supply Buphenyl-specific trial IDs or an FDA trial snapshot.)
What are the key endpoints and safety considerations in Buphenyl UCD studies?
Answer (featured snippet): The dominant endpoints are ammonia control and prevention of hyperammonemic crises, paired with long-term tolerability in chronic administration.
Endpoints used in practice
- Plasma/urine ammonia trends (control stability rather than single-point reduction)
- Incidence of hyperammonemic events
- Hospitalizations/emergency visits from metabolic decompensation
- Adherence feasibility in pediatric and caregiver settings
Safety considerations that influence prescribing and payer continuation
- Gastrointestinal adverse events
- Protein/nutritional management, since UCD diets and ammonia control interact
- Long-term monitoring burdens for chronic therapy
Market analysis: What is the addressable market for Buphenyl in the US and how is it growing?
Answer (featured snippet): The addressable market is constrained by rare disease prevalence, but growth comes from diagnosis rates, specialty referral networks, and increasing UCD patient retention on chronic therapy.
Demand drivers
- Diagnosis and newborn screening
- Higher identification of UCD cases expands the treated base over time.
- Specialty center adoption
- UCD centers standardize regimens; switching costs increase persistence.
- Payer formulary dynamics
- Specialty tiers and prior authorization requirements affect uptake.
Constraint drivers
- Lower prevalence growth than common disease areas
- Competitive displacement risk from better-tolerated or more convenient ammonia therapies
- Chronic cost pressure and step-therapy policies
Revenue projection: What market share and sales trajectory is realistic for Buphenyl?
Answer (featured snippet): Buphenyl’s sales trajectory is likely to track rare-disease patient growth and persistence rather than sharp label expansion. Competitive pressure from newer phenylbutyrate delivery forms and other ammonia-lowering agents can limit share growth.
Projection framework used for specialty rare chronic therapies
- Treated patient pool growth (diagnosis + persistence)
- Retention vs switching rate (driven by tolerability and convenience)
- Net price erosion (rebates and payer negotiation)
- Cannibalization from competing ammonia-lowering regimens
(Note: A numeric projection requires baseline sales, current market share, and payer/net price assumptions which are not included in the prompt. Without them, no complete, accurate forward model can be produced.)
What generic entry risks exist for Buphenyl and what manufacturing/IP barriers apply?
Answer (featured snippet): Entry risk depends on any still-in-force formulation/process patents and on Orange Book patent listings. If listed patents are minimal or expired, generics can pressure price, shifting volume to lower-cost alternatives.
Manufacturing/IP barriers that can slow entry
- Specific process parameters that affect polymorph/stability/particle profile
- Excipient systems for taste and pediatric dosing
- Stability data requirements for chronic dispensing
Litigation trigger points in practice
- Paragraph IV filings against listed patents
- Settlement-driven “at-risk launch” periods
(Note: Requires Orange Book patent list and any litigation docket data to quantify.)
What patent litigation affects Buphenyl, and where are settlements likely to shape launch timing?
Answer (featured snippet): For legacy small-molecule rare disease products, litigation typically centers on formulation/process patents and can produce entry delays via settlements. A precise map requires known case numbers and listed patents.
(Note: No litigation identifiers were provided, so no accurate litigation status can be stated.)
Key Takeaways
- Buphenyl is a mature, chronic UCD ammonia-management therapy; current business focus centers on persistence, tolerability, and competition more than new clinical efficacy breakthroughs.
- Generic or biosimilar-style disruption is unlikely as a concept for Buphenyl (it is not biologic), but small-molecule generic entry risk can still be material depending on remaining Orange Book-listed patents and any active litigation.
- A credible exclusivity and entry-timing view requires a specific Orange Book record for Buphenyl’s NDA and listed patents, plus any active case dockets.
- Market growth is modest but durable, driven by diagnosis and treated patient continuity; competitive displacement from more convenient ammonia-lowering therapies is the main share variable.
FAQs
- Which urea cycle disorders does Buphenyl labeling cover and what is the practical prescribing scope?
- Does Buphenyl have any pediatric dosing restrictions, titration rules, or monitoring requirements in the label?
- How do UCD specialty centers decide between Buphenyl and alternative phenylbutyrate delivery products?
- What formulation characteristics (dose form, stability, taste mitigation) most affect switching from Buphenyl to competitors?
- What Orange Book patents commonly block generic sodium phenylbutyrate products and how does that differ by dosage form?
References
- [No citable sources were provided in the prompt. No references can be listed without verifiable source data.]
